AXIM Biotechnologies, Inc. and Medical Marijuana, Inc. Enter into Strategic Alliance to Research and Develop Applications and Uses of Patent for Water Soluble Cannabinoids

by Kyle | Jan 29, 2026 | Press Release

SAN DIEGO, CA – (NewMediaWire) – January 29, 2026 – AXIM Biotechnologies, Inc. (OTC: AXIM) (the “Company”) today announced a strategic alliance with Medical Marijuana, Inc. (OTC: MJNA) intended to research and develop applications and...

AXIM Biotechnologies Engages 624 Advisors, owned and managed by Dr. Alan J. Touch, Innovator and Global Regulatory Leader, as Chief Medical & Regulatory Affairs Advisor

by Kyle | Jan 20, 2026 | Press Release

San Diego, CA — Jan 20 2026  — AXIM Biotechnologies, Inc. (“AXIM” or the “Company”), a diagnostic and biotechnology company advancing clinically validated solutions for ocular and inflammatory diseases, today announced the engagement of 624 Advisors, which is owned...

AXIM Biotechnologies, Inc. Announces Exclusive Distribution Agreement with VisionPlus Corp. for TearScan® Lactoferrin and IgE Diagnostic Tests in South Korea

by Kyle | Oct 23, 2025 | Press Release

San Diego, CA — October 23, 2025 — AXIM Biotechnologies, Inc. (“AXIM”), a leader in rapid, point-of-care ocular diagnostics, today announced it has entered into an exclusive distribution agreement with VisionPlus Corp. (“VisionPlus”) to market and distribute...

AXIM Biotechnologies Announces Exclusive Latin America License & Distribution Agreement With JK Medical for TearScan(R) Ocular Diagnostic Tests

by Kyle | Oct 7, 2025 | Press Release

Countries: Brazil, Chile, Peru, Argentina, Mexico, Ecuador, Colombia SAN DIEGO, CA – October 7, 2025 (NEWMEDIAWIRE) – AXIM Biotechnologies, Inc. (OTC: AXIM), a diagnostics company focused on rapid, point-of-care ophthalmic testing, today announced it has...

Axim Biotechnologies Files Pre-Submission with FDA for CLIA Waiver Pathway on Lactoferrin Point-of-Care Diagnostic Test

by Kyle | Jun 24, 2025 | Press Release

San Diego, CA – June 24, 2025 – Axim Biotechnologies, Inc. (OTCQB: AXIM), a leading developer of rapid diagnostic testing for ocular and systemic conditions, today announced that it has filed a Pre-Submission (Pre-Sub Q) with the U.S. Food and Drug Administration...